- Chiasma Inc CHMA submitted a marketing application to the European Medicines Agency seeking approval of Mycapssa (oral octreotide capsules) as maintenance therapy for adults with acromegaly.
- The application is supported by positive results from Phase 3 MPOWERED non-inferiority trial comparing Mycapssa to long-acting injectable somatostatin analogs (iSSAs).
- Recently, the company announced positive patient-reported outcomes data from its MPOWERED trial, demonstrating that study patients reported significantly improved quality of life and work productivity after transitioning from long-acting injectable somatostatin analogs to Mycapssa.
- Price Action: CHMA shares are down 0.2% at $4.7 during the premarket session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
